Down-titration of omalizumab in a patient with chronic spontaneous urticaria

Abstract

Background: Omalizumab was demonstrated to be effective in patients with chronic urticaria resistant to antihistamines and is recommended as an add-on, third line treatment for such subjects.

Patient and results: This article reports the history of a patient affected by chronic spontaneous urticaria, unresponsive to antihistamines, who received omalizumab, according to a personalized schedule. Prolonged administration of low dosage drug provided a good and long-lasting control of symptoms.

Conclusion: This experience suggests that omalizumab could be used at low dose, with personalized plans, to reduce the risk of adverse events and costs of treatment.

KEYWORDS:

• Omalizumab
• chronic spontaneous urticarial
• personalized treatment plan

Acknowledgement

Medical writing assistance of this paper was provided by Laura Brogelli, on behalf of Content Ed Net; this assistance was funded by Novartis.

Funding

This supplement was funded by Novartis.

Disclosure statement

No potential conflict of interest was reported by the authors.